Linezolid underexposure in a patient co-treated with venlafaxine

European Journal of Clinical Pharmacology

Volumn 71, Issue 10, 2015, Pages 1285-1286

  Cojutti, Piergiorgio ^a,b   Crapis, Massimo ^a   Bassetti, Matteo ^a   Hope, William ^c   Pea, Federico ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LEVOFLOXACIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; PRAMIPEXOLE; PROCALCITONIN; VENLAFAXINE; ANTIINFECTIVE AGENT;

AGED; ANTIMICROBIAL THERAPY; ARTICLE; CASE REPORT; COUGHING; DRUG DOSE INCREASE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEVER; HUMAN; MALE; MESOTHELIOMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STREPTOCOCCUS ORALIS; STREPTOCOCCUS PARASANGUINIS; THORACOCENTESIS; THORACOSCOPY; AREA UNDER THE CURVE; DOSE RESPONSE; MULTIDRUG RESISTANCE; STREPTOCOCCAL INFECTIONS;

AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; LINEZOLID; MALE; STREPTOCOCCAL INFECTIONS; VENLAFAXINE HYDROCHLORIDE;

EID: 84941317408     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1922-z     Document Type: Article

References (10)

1. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M (2012) Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67(8):2034-2042. doi: 10.1093/jac/dks153
2. Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42(13):1129-1140. doi: 10.2165/00003088-200342130-00004
3. Pea F, Scudeller L, Lugano M, Baccarani U, Pavan F, Tavio M, Furlanut M, Rocca GD, Bresadola F, Viale P (2006) Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 42(3):434-435. doi: 10.1086/499533
4. Pea F, Cadeo B, Cojutti PG, Pecori D, Bassetti M (2014) Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: a case report. Ther Drug Monit 36(5):687-689. doi: 10.1097/FTD.0000000000000069
5. Egle H, Trittler R, Kummerer K, Lemmen SW (2005) Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 77(5):451-453. doi: 10.1016/j.clpt.2005.01.020
6. Levin GM, Nelson LA, DeVane CL, Preston SL, Eisele G, Carson SW (2001) A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull 35(2):62-71
7. Ehret MJ, Levin GM, Narasimhan M, Rathinavelu A (2007) Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum Psychopharmacol 22(1):49-53. doi: 10.1002/hup.820
8. Bachmeier CJ, Beaulieu-Abdelahad D, Ganey NJ, Mullan MJ, Levin GM (2011) Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Biopharm Drug Dispos 32(4):233-244. doi: 10.1002/bdd.753
9. Zoller M, Maier B, Hornuss C, Neugebauer C, Dobbeler G, Nagel D, Holdt LM, Bruegel M, Weig T, Grabein B, Frey L, Teupser D, Vogeser M, Zander J (2014) Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care 18(4):R148. doi: 10.1186/cc13984
10. Spina E, Trifiro G, Caraci F (2012) Clinically significant drug interactions with newer antidepressants. CNS Drugs 26(1):39-67. doi: 10.2165/11594710-000000000-00000